Biotechnology company Moderna Inc (Nasdaq:MRNA) reported on Thursday that the US government has purchased an additional 100m doses of its COVID-19 Vaccine to bring its confirmed order commitment to 300m doses.
The company is on track to deliver the first 100m doses in the Q1 2021 and the second order of 100m doses in the Q2 2021. It is working with its domestic manufacturing partners and the US FDA to continue to explore ways to accelerate delivery of the vaccine. It will continue to leverage the US -based manufacturing infrastructure to supply the COVID-19 Vaccine to the US government.
According to the company, it has supplied 41m released doses of the vaccine to the US government to date. More than 22m Americans have received the Moderna COVID-19 Vaccine in the US, according to the US Centers for Disease Control and Prevention.
This COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and the National Institute of Allergy and Infectious Disease's (NIAID) Vaccine Research Centre.
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy
Centivax raises USD45m to commercialise universal flu vaccine
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval